The group's principal activity is to seek to license its technologies and realize value from its assets. It also seeks to use a portion of its available cash to acquire technologies or products or to acquire or invest in companies. In Dec 2001, the group organized a wholly owned subsidiary, cadus technologies, inc and transferred its yeast-based drug discovery technologies to the subsidiary. On 19-Dec-2001, the subsidiary licensed its yeast-based drug discovery technologies including various reagents and its library of over 25,000 yeast strains, on a non-exclusive basis to osi pharmaceuticals, inc.
